ALK and non-small cell lung carcinoma: Metastasis into the central nervous system is a common complication of NSCLC patients carrying mutant ALK undergoing treatment with crizotinib, and second generation TKIs, namely alectinib, have demonstrated therapeutic activity in treating central nervous system metastasis in ALK-positive NSCLC patients [95].